Pembrolizumab in High-risk Thyroid Cancer

This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.

Trial Details

NCT ID
NCT05852223
Phase
PHASE2
Sponsor
Istituti Clinici Scientifici Maugeri SpA
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • Pembrolizumab
Locations (sample)
  • Pavia, Lombardy, Italy|45.19205,9.15917

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of differe…
  • Patients with a risk \> 20% for persistent/recurrent disease: primary tumor \> 4 cm; multifocal papillary microcarcinoma with extra tumor extension…
  • Poorly differentiated carcinoma; Hurtle cell carcinoma.
  • Patients with distant metastasis at diagnosis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →